[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2021014051A - Nuevo compuesto peptidico o sal farmaceuticamente aceptable del mismo. - Google Patents

Nuevo compuesto peptidico o sal farmaceuticamente aceptable del mismo.

Info

Publication number
MX2021014051A
MX2021014051A MX2021014051A MX2021014051A MX2021014051A MX 2021014051 A MX2021014051 A MX 2021014051A MX 2021014051 A MX2021014051 A MX 2021014051A MX 2021014051 A MX2021014051 A MX 2021014051A MX 2021014051 A MX2021014051 A MX 2021014051A
Authority
MX
Mexico
Prior art keywords
pharmaceutically acceptable
acceptable salt
peptide compound
novel peptide
novel
Prior art date
Application number
MX2021014051A
Other languages
English (en)
Inventor
Yoo Seok Kim
Myoung Hwan Kim
Young In Kim
Taek Joo Lim
Hyeong Joon Lim
Jee Young Kim
Eun Young Park
Original Assignee
Eyebio Korea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eyebio Korea filed Critical Eyebio Korea
Publication of MX2021014051A publication Critical patent/MX2021014051A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/54—Proteins
    • A23V2250/55—Peptide, protein hydrolysate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/10—General cosmetic use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Birds (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

La presente invención se refiere a un nuevo compuesto peptídico o una sal farmacéuticamente aceptable del mismo.
MX2021014051A 2019-05-21 2020-05-20 Nuevo compuesto peptidico o sal farmaceuticamente aceptable del mismo. MX2021014051A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190059628 2019-05-21
PCT/KR2020/006594 WO2020235932A1 (ko) 2019-05-21 2020-05-20 신규한 펩타이드 화합물 또는 이의 약제학적으로 허용 가능한 염

Publications (1)

Publication Number Publication Date
MX2021014051A true MX2021014051A (es) 2022-02-11

Family

ID=73458705

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014051A MX2021014051A (es) 2019-05-21 2020-05-20 Nuevo compuesto peptidico o sal farmaceuticamente aceptable del mismo.

Country Status (12)

Country Link
US (2) US20240228538A1 (es)
EP (1) EP3974441A4 (es)
JP (1) JP7576048B2 (es)
KR (2) KR20200134175A (es)
CN (1) CN114269769A (es)
AU (1) AU2020277930B2 (es)
BR (1) BR112021023477A2 (es)
CA (1) CA3139411A1 (es)
MX (1) MX2021014051A (es)
SG (1) SG11202112276RA (es)
WO (1) WO2020235932A1 (es)
ZA (1) ZA202109175B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020235932A1 (ko) * 2019-05-21 2020-11-26 주식회사 아이바이오코리아 신규한 펩타이드 화합물 또는 이의 약제학적으로 허용 가능한 염
MX2024006997A (es) * 2021-12-13 2024-06-19 Eyebiokorea Inc Composicion para el tratamiento de la degeneracion macular que comprende un nuevo peptido.
KR102593936B1 (ko) * 2021-12-13 2023-10-27 주식회사 아이바이오코리아 신규한 펩타이드를 포함하는 황반변성의 치료용 조성물
KR20230089987A (ko) 2021-12-14 2023-06-21 주식회사 아이바이오코리아 펩타이드 약물을 포함하는 안구 투여용 약학 조성물
KR102587729B1 (ko) * 2023-02-27 2023-10-12 주식회사 아이바이오코리아 펩타이드를 포함하는 당뇨망막병증의 치료용 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084555A (en) * 1989-08-21 1992-01-28 The Administrators Of The Tulane Educational Fund An octapeptide bombesin analog
IT1241761B (it) * 1990-08-03 1994-02-01 Menarini Farma Ind Peptidi di sintesi antagonisti della neurochinina a, loro sali e relativi procedimenti di fabbricazione
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
WO2004074312A2 (en) * 2003-02-05 2004-09-02 University Of Ulster Tryptophyllin peptides and uses thereof
EP1858538B1 (en) 2005-01-20 2019-03-27 Biomarck Pharmaceuticals, Ltd. Mucin hypersecretion inhibitors based on the structure of mans and methods of use
US8378070B2 (en) 2007-03-12 2013-02-19 Ramot At Tel-Aviv University Ltd. Peptides for the regulation of neurotransmitter sequestration and release
WO2009046832A2 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Short peptides used in medicine
US20090074672A1 (en) 2007-09-17 2009-03-19 Sri International Tumor Boundary Imaging
WO2011060349A1 (en) 2009-11-13 2011-05-19 North Carolina State University Methods of modulating mesenchymal stem cells
MX356343B (es) * 2012-04-13 2018-05-23 Lubrizol Advanced Mat Inc Compuestos que inhiben la exocitosis neuronal (ii).
KR101721059B1 (ko) * 2014-12-26 2017-03-30 주식회사 아이바이오코리아 안구 표면 질환 예방 또는 치료용 약학조성물
ES2819030T3 (es) * 2016-04-08 2021-04-14 Eyebio Korea Péptido basado en colágeno tipo II alfa-1 útil para el tratamiento de una enfermedad de la superficie ocular
KR101798183B1 (ko) * 2016-04-08 2017-11-15 주식회사 아이바이오코리아 건성안 예방 또는 치료용 약학조성물
KR101795650B1 (ko) * 2016-05-12 2017-11-09 인제대학교 산학협력단 아플리버셉트-콜라겐 타입 ii 펩타이드의 키메라 단백질을 유효성분으로 함유하는 혈관신생 억제용 조성물
EP3475293A4 (en) * 2016-06-28 2020-03-11 Valorisation-Recherche, Limited Partnership NEW CYCLIC PEPTIDES AND USES THEREOF
ES2982308T3 (es) * 2017-05-17 2024-10-15 Yuyu Pharma Inc Péptido novedoso y composición farmacéutica para tratar una enfermedad ocular que comprende el mismo como un ingrediente farmacéutico activo
WO2020235932A1 (ko) * 2019-05-21 2020-11-26 주식회사 아이바이오코리아 신규한 펩타이드 화합물 또는 이의 약제학적으로 허용 가능한 염

Also Published As

Publication number Publication date
KR20200134175A (ko) 2020-12-01
US20240352071A1 (en) 2024-10-24
AU2020277930B2 (en) 2024-06-13
CN114269769A (zh) 2022-04-01
SG11202112276RA (en) 2021-12-30
ZA202109175B (en) 2024-04-24
EP3974441A1 (en) 2022-03-30
WO2020235932A1 (ko) 2020-11-26
EP3974441A4 (en) 2023-10-18
BR112021023477A2 (pt) 2022-02-15
KR20220062252A (ko) 2022-05-16
JP7576048B2 (ja) 2024-10-30
CA3139411A1 (en) 2020-11-26
US20240228538A1 (en) 2024-07-11
AU2020277930A1 (en) 2021-12-09
JP2022533991A (ja) 2022-07-27
KR102523943B1 (ko) 2023-04-20

Similar Documents

Publication Publication Date Title
ZA202109175B (en) Novel peptide compound or pharmaceutically acceptable salt thereof
MX2020012723A (es) Compuestos.
MY197700A (en) Compounds useful for inhibiting cdk7
ZA202206923B (en) New methylquinazolinone derivatives
MX2021010783A (es) Formulaciones de anticuerpo anti-il-36r.
MX2023014281A (es) Lipidos novedosos.
PH12020500341A1 (en) Pentacyclic compound
PH12021550102A1 (en) Cardiosafe antidiabetic therapy
MX2018001517A (es) Derivados sustituidos de guanidina.
MY193239A (en) Novel b-lactamase inhibitors
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
MX2021009261A (es) Compuesto de fluorovinilbenzamida como inmunomodulador pd-l1.
PH12021550452A1 (en) Methods of treating mycobacterial infections using tetracycline compounds
EP4049680A4 (en) NEW SUBSTITUTED CONDENSED RING CONNECTION
EP3978510A4 (en) NOROVIRUS BINDING PEPTIDE
SG11201803867TA (en) Sodium channel blocker
MX2020008689A (es) Composicion herbicida que comprende por lo menos un compuesto activo fenolico.
ZA202205158B (en) Polypeptide having mmp2-inhibitory effect
ZA202105425B (en) A novel compound derived from allulose
EP3978511A4 (en) NOROVIRUS BINDING PEPTIDE
ZA202205170B (en) Process and intermediate for the preparation of oxetan-2-ylmethanamine
TWI799615B (zh) 新穎的聚醯氧甲基-4,4'-醯氧基聯苯化合物
WO2020043749A8 (en) New delivery system
TR201721065A2 (tr) Deksmedetomi̇di̇n i̇çeren li̇yofi̇li̇ze farmasöti̇k formülasyonlar
SA119400353B1 (ar) مشتق بيرازول مستبدل